Braveheart is a clinical-stage biopharmaceutical company developing BHB-1893, a selective small-molecule cardiac myosin inhibitor designed to improve heart performance in patients with hypertrophic cardiomyopathy (HCM). The company is advancing this investigational treatment through global late-stage clinical development, targeting a rare disease affecting approximately 1 in 500 individuals in the United States.
Funding
Funding not disclosed
Founders
Product
Problem
Hypertrophic cardiomyopathy (HCM) is among the most common rare diseases, affecting approximately 1 in 500 individuals in the United States. In HCM, the heart muscle becomes abnormally thickened, causing inefficient pumping and filling of blood, which can lead to symptoms such as shortness of breath, chest pain, fatigue, and fainting.
Solution
Braveheart is a biopharmaceutical company focused on transforming the standard of care for hypertrophic cardiomyopathy and related conditions. The company is developing BHB-1893, a selective, small-molecule cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By targeting the underlying mechanism of the disease, BHB-1893 aims to address the root cause of impaired cardiac function rather than merely managing symptoms. Braveheart is currently advancing BHB-1893 through global late-stage clinical development, with the goal of bringing this investigational treatment to patients who currently have limited therapeutic options.
Target Audience
Primary customers are patients diagnosed with hypertrophic cardiomyopathy and the cardiologists and healthcare providers who treat them, as well as clinical research sites participating in late-stage trials.
Features
- BHB-1893 is a selective, small-molecule cardiac myosin inhibitor designed to directly improve heart muscle performance
- The compound targets the underlying pathophysiology of HCM by modulating cardiac myosin activity
- Currently in global late-stage clinical development as an investigational treatment for HCM
- Pipeline focused exclusively on HCM and related conditions, allowing for deep specialization in cardiac muscle disease